Mesenchymal stem cells in tissue repair

Frontiers in Immunology

Volumn 4, Issue JUL, 2013, Pages

  DiMarino, Amy M ^a   Caplan, Arnold I ^b   Bonfield, Tracey L ^c  

^a Pediatric Pulmonology   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adult mesenchymal stem cells; Anti Inflammatory agents; Anti microbial protein; Milieu therapy; Regenerative pharmacology

Indexed keywords

NITRIC OXIDE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ALPHA4 INTEGRIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR; INDOLEAMINE 2, 3 DIOXYGENASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PEPTIDES AND PROTEINS; PROTEIN KINASE B; PROTEIN TSG 6; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE LUNG INJURY; ADIPOCYTE; ASTHMA; BACTERICIDAL ACTIVITY; CARTILAGE CELL; CELL DIFFERENTIATION; FETAL CALF SERUM; GRAFT VERSUS HOST REACTION; HEART INFARCTION; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; LUPUS VULGARIS; MESENCHYMAL STEM CELL; MILIEU THERAPY; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOBLAST; PERICYTE; REGENERATIVE MEDICINE; REVIEW; SEPSIS; TISSUE REPAIR; WOUND HEALING; BONE; CLINICAL TRIAL (TOPIC); MESENCHYMAL STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; SCORING SYSTEM; SURVIVAL;

EID: 84883729239     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00201     Document Type: Review

References (82)

1. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol (2009) 217:318-24. doi:10.1002/path.2469
2. Tian H, Wu DP, Chen GH. Current research advance on abnormalities of mesenchymal stem cells in hematological malignancies. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2011) 19:1319-24.
3. Patel SA, Sherman L, Munoz J, Rameshwar P. Immunological properties of mesenchymal stem cells and clinical implications. Arch Immunol Ther Exp (Warsz) (2008) 56:1-8. doi:10.1007/s00005-008-0001-x
4. Matthay MA. Advances and challenges in translating stem cell therapies for clinical diseases. Transl Res (2010) 156:107-11. doi:10.1016/j.trsl.2010.07.007
5. Cook MM, Futrega K, Osiecki M, Kabiri M, Kul B, Rice A, et al. Micromarrows? 3D co-culture of haematopoietic stem cells and mesenchymal stromal cells. Tissue Eng Part C Methods (2012) 18:319-28. doi:10.1089/ten.TEC.2011.0159
6. Bonfield TL, Nolan Koloze MT, Lennon DP, Caplan AI. Defining human mesenchymal stem cell efficacy in vivo. J Inflamm (Lond) (2010) 7:51. doi:10.1186/1476-9255-7-51
7. Tian Y, Deng YB, Huang YJ, Wang Y. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Immunol Invest (2008) 37:29-42. doi:10.1080/08820130701410223
8. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant (2010) 16:838-47. doi:10.1016/j.bbmt.2010.01.011
9. Bobis S, Jarocha D, Majka M. Mesenchymal stem cells: characteristics and clinical applications. Folia Histochem Cytobiol (2006) 44:215-30.
10. Brooke G, Rossetti T, Ilic N, Murray P, Hancock S, Pelekanos R, et al. Points to consider in designing mesenchymal stem cell-based clinical trials. Transfus Med Hemother (2008) 35:279-85. doi:10.1159/000143158
11. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med (2007) 262:509-25. doi:10.1111/j.1365-2796.2007.01844.x
12. Dennis JE, Caplan AI. Differentiation potential of conditionally immortalized mesenchymal progenitor cells from adult marrow of a H-2Kb-tsA58 transgenic mouse. J Cell Physiol (1996) 167:523-38. doi:10.1002/(SICI)1097-4652(199606)167:3<523::AID-JCP16>3.3.CO;2-E
13. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 8:315-7. doi:10.1080/14653240600855905
14. Dennis JE, Merriam A, Awadallah A, Yoo JU, Johnstone B, Caplan AI. A quadripotential mesenchymal progenitor cell isolated from the marrow of an adult mouse. J Bone Miner Res (1999) 14:700-9. doi:10.1359/jbmr.1999.14.5.700
15. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood (2005) 105:2214-9. doi:10.1182/blood-2004-07-2921
16. Jarvinen L, Badri L, Wettlaufer S, Ohtsuka T, Standiford TJ, Toews GB, et al. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J Immunol (2008) 181:4389-96.
17. Bonfield TL, Caplan AI. Adult mesenchymal stem cells: an innovative therapeutic for lung diseases. Discov Med (2010) 9:337-45.
18. Caplan AI. All MSCs are pericytes? Cell Stem Cell (2008) 3:229-30. doi:10.1016/j.stem.2008.08.008
19. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell (2008) 3:301-13. doi:10.1016/j.stem.2008.07.003
20. Solchaga LA, Welter JF, Lennon DP, Caplan AI. Generation of pluripotent stem cells and their differentiation to the chondrocytic phenotype. Methods Mol Med (2004) 100:53-68.
21. Solchaga LA, Penick K, Porter JD, Goldberg VM, Caplan AI, Welter JF. FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. J Cell Physiol (2005) 203:398-409. doi:10.1002/jcp.20238
22. Solchaga LA, Penick K, Goldberg VM, Caplan AI, Welter JF. Fibroblast growth factor-2 enhances proliferation and delays loss of chondrogenic potential in human adult bone-marrow-derived mesenchymal stem cells. Tissue Eng Part A (2010) 16:1009-19. doi:10.1089/ten.TEA.2009.0100
23. Dominici M, Hofmann TJ, Horwitz EM. Bone marrow mesenchymal cells: biological properties and clinical applications. J Biol Regul Homeost Agents (2001) 15:28-37.
24. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science (1999) 284:143-7. doi:10.1126/science.284.5411.143
25. Dennis JE, Haynesworth SE, Young RG, Caplan AI. Osteogenesis in marrow-derived mesenchymal cell porous ceramic composites transplanted subcutaneously: effect of fibronectin and laminin on cell retention and rate of osteogenic expression. Cell Transplant (1992) 1:23-32.
26. Dennis JE, Konstantakos EK, Arm D, Caplan AI. In vivo osteogenesis assay: a rapid method for quantitative analysis. Biomaterials (1998) 19:1323-8. doi:10.1016/S0142-9612(97)00170-1
27. Dennis JE, Caplan AI. Porous ceramic vehicles for rat-marrow-derived (Rattus norvegicus) osteogenic cell delivery: effects of pre-treatment with fibronectin or laminin. J Oral Implantol (1993) 19:106-15.
28. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol (1996) 166:585-92. doi:10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.3.CO;2-7
29. Bonfield TL, Barna BP, John N, Malur A, Culver DA, Kavuru MS, et al. Suppression of activin A in autoimmune lung disease associated with anti-GM-CSF. J Autoimmun (2006) 26:37-41. doi:10.1016/j.jaut.2005.10.004
30. Rasmusson I, Uhlin M, Le Blanc K, Levitsky V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol (2007) 82:887-93. doi:10.1189/jlb.0307140
31. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 65:55-63. doi:10.1016/0022-1759(83)90303-4
32. Abdallah BM, Kassem M. Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther (2008) 15:109-16. doi:10.1038/sj.gt.3303067
33. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med (2010) 182:1047-57. doi:10.1164/rccm.201001-0010OC
34. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia (2009) 57:1192-203. doi:10.1002/glia.20841
35. Miller RH, Bai L, Lennon DP, Caplan AI. The potential of mesenchymal stem cells for neural repair. Discov Med (2010) 9:236-42.
36. Miller RH, Bai L. Cellular approaches for stimulating CNS remyelination. Regen Med (2007) 2:817-29. doi:10.2217/17460751.2.5.817
37. Matthay MA, Thompson BT, Read EJ, McKenna DH Jr, Liu KD, Calfee CS, et al. Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest (2010) 138:965-72. doi:10.1378/chest.10-0518
38. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells (2010) 28:2229-38. doi:10.1002/stem.544
39. Matthay MA, Goolaerts A, Howard JP, Lee JW. Mesenchymal stem cells for acute lung injury: preclinical evidence. Crit Care Med (2010) 38:S569-73. doi:10.1097/CCM.0b013e3181f1ff1d
40. Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM. Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res (2011) 12:114. doi:10.1186/1465-9921-12-114
41. Larghero J, Vija L, Lecourt S, Michel L, Verrecchia F, Farge D. Mesenchymal stem cells and immunomodulation: toward new immunosuppressive strategies for the treatment of autoimmune diseases? Rev Med Interne (2009) 30:287-99. doi:10.1016/j.revmed.2008.08.019
42. Le BK. Mesenchymal stromal cells: tissue repair and immune modulation. Cytotherapy (2006) 8:559-61. doi:10.1080/14653240601045399
43. da Silva ML, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells (2008) 26:2287-99. doi:10.1634/stemcells.2007-1122
44. Arima N, Nakamura F, Fukunaga A, Hirata H, Machida H, Kouno S, et al. Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study. Cytotherapy (2010) 12:265-8. doi:10.3109/14653240903390795
45. Price MJ, Chou CC, Frantzen M, Miyamoto T, Kar S, Lee S, et al. Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. Int J Cardiol (2006) 111:231-9. doi:10.1016/j.ijcard.2005.07.036
46. Weiss DJ, Berberich MA, Borok Z, Gail DB, Kolls JK, Penland C, et al. Adult stem cells, lung biology, and lung disease. NHLBI/Cystic Fibrosis Foundation Workshop. Proc Am Thorac Soc (2006) 3:193-207. doi:10.1513/pats.200601-013MS
47. Matthay MA. Treatment of acute lung injury: clinical and experimental studies. Proc Am Thorac Soc (2008) 5:297-9. doi:10.1513/pats.200708-141DR
48. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem (2006) 98:1076-84. doi:10.1002/jcb.20886
49. Dennis JE, Cohen N, Goldberg VM, Caplan AI. Targeted delivery of progenitor cells for cartilage repair. J Orthop Res (2004) 22:735-41. doi:10.1016/j.orthres.2003.12.002
50. Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm Res (2007) 24:819-41. doi:10.1007/s11095-006-9216-x
51. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med (2005) 11:367-8. doi:10.1038/nm0405-367
52. Chamberlain JR, Deyle DR, Schwarze U, Wang P, Hirata RK, Li Y, et al. Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. Mol Ther (2008) 16:187-93. doi:10.1038/sj.mt.6300339
53. Deyle DR, Khan IF, Ren G, Wang PR, Kho J, Schwarze U, et al. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. Mol Ther (2012) 20:204-13. doi:10.1038/mt.2011.209
54. Sackstein R. Glycoengineering of HCELL, the human bone marrow homing receptor: sweetly programming cell migration. Ann Biomed Eng (2012) 40:766-76. doi:10.1007/s10439-011-0461-8
55. Burdick MM, Chu JT, Godar S, Sackstein R. HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells. J Biol Chem (2006) 281:13899-905. doi:10.1074/jbc.M513617200
56. Sng J, Lufkin T. Emerging stem cell therapies: treatment, safety, and biology. Stem Cells Int (2012) 23:1383-9. doi:10.1155/2012/521343
57. De Ugarte DA, Alfonso Z, Zuk PA, Elbarbary A, Zhu M, Ashjian P, et al. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett (2003) 89:267-70. doi:10.1016/S0165-2478(03)00108-1
58. Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood (2011) 118:330-8. doi:10.1182/blood-2010-12-327353
59. Oh JY, Roddy GW, Choi H, Lee RH, Ylostalo JH, Rosa RH Jr, et al. Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci U S A (2010) 107:16875-80. doi:10.1073/pnas.1012451107
60. Heldens GT, Davidson EN, Vitters EL, Schreurs BW, Piek E, Berg WB, et al. Catabolic factors and osteoarthritis-conditioned medium inhibit chondrogenesis of human mesenchymal stem cells. Tissue Eng Part A (2012) 18:45-54. doi:10.1089/ten.TEA.2011.0083
61. Wu H, Lu W, Mahato RI. Mesenchymal stem cells as a gene delivery vehicle for successful islet transplantation. Pharm Res (2011) 28:2098-109. doi:10.1007/s11095-011-0434-5
62. Volarevic V, Al-Qahtani A, Arsenijevic N, Pajovic S, Lukic ML. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity (2010) 43:255-63. doi:10.3109/08916930903305641
63. Chen K, Wang D, Du WT, Han ZB, Ren H, Chi Y, et al. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol (2010) 135:448-58. doi:10.1016/j.clim.2010.01.015
64. Yun SP, Ryu JM, Jang MW, Han HJ. Interaction of profilin-1 and F-actin via a beta-arrestin-1/JNK signaling pathway involved in prostaglandin E(2)-induced human mesenchymal stem cells migration and proliferation. J Cell Physiol (2011) 226:559-71. doi:10.1002/jcp.22366
65. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant (2010) 19:667-79. doi:10.3727/096368910X508762
66. Lanz TV, Opitz CA, Ho PP, Agrawal A, Lutz C, Weller M, et al. Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells Dev (2010) 19:657-68. doi:10.1089/scd.2009.0385
67. Tomic S, Djokic J, Vasilijic S, Vucevic D, Todorovic V, Supic G, et al. Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists. Stem Cells Dev (2011) 20:695-708. doi:10.1089/scd.2010.0145
68. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol (2012) 67:1-8. doi:10.1111/j.1600-0897.2011.01069.x
69. Amin AH, Abd Elmageed ZY, Nair D, Partyka MI, Kadowitz PJ, Belmadani S, et al. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest (2010) 90:985-96. doi:10.1038/labinvest.2010.86
70. Bonfield TL, Koloze M, Lennon DP, Zuchowski B, Yang SE, Caplan AI. Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. Am J Physiol Lung Cell Mol Physiol (2010) 299:L760-70. doi:10.1152/ajplung.00182.2009
71. Bhakta NR, Woodruff PG. Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev (2011) 242:220-32. doi:10.1111/j.1600-065X.2011.01032.x
72. Bellone G, Scirelli T, Emanuelli G. Osteo-promoting activity of osteoplant angiostad in vitro. Minerva Stomatol (2008) 57:189-98.
73. Kunzmann S, Wright JR, Steinhilber W, Kramer BW, Blaser K, Speer CP, et al. TGF-beta1 in SP-A preparations influence immune suppressive properties of SP-A on human CD4+ T lymphocytes. Am J Physiol Lung Cell Mol Physiol (2006) 291:L747-56. doi:10.1152/ajplung.00401.2005
74. Kintscher U, Wakino S, Bruemmer D, Goetze S, Graf K, Hsueh WA, et al. TGF-beta(1) induces peroxisome proliferator-activated receptor gamma1 and gamma2 expression in human THP-1 monocytes. Biochem Biophys Res Commun (2002) 297:794-9. doi:10.1016/S0006-291X(02)02264-7
75. Liu H, Liu S, Li Y, Wang X, Xue W, Ge G, et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS ONE (2012) 7:e34608. doi:10.1371/journal.pone.0034608
76. Liu X, Duan B, Cheng Z, Jia X, Mao L, Fu H, et al. SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. Protein Cell (2011) 2:845-54. doi:10.1007/s13238-011-1097-z
77. Ma M, Ye JY, Deng R, Dee CM, Chan GC. Mesenchymal stromal cells may enhance metastasis of neuroblastoma via SDF-1/CXCR4 and SDF-1/CXCR7 signaling. Cancer Lett (2011) 312:1-10. doi:10.1016/j.canlet.2011.06.028
78. Schantz JT, Chim H, Whiteman M. Cell guidance in tissue engineering: SDF-1 mediates site-directed homing of mesenchymal stem cells within three-dimensional polycaprolactone scaffolds. Tissue Eng (2007) 13:2615-24. doi:10.1089/ten.2006.0438
79. Jang MW, Yun SP, Park JH, Ryu JM, Lee JH, Han HJ. Cooperation of Epac1/Rap1/Akt and PKA in prostaglandin E(2)-induced proliferation of human umbilical cord blood derived mesenchymal stem cells: involvement of c-Myc and VEGF expression. J Cell Physiol (2012) 227:3756-67. doi:10.1002/jcp.24084
80. Lee SH, Lee YJ, Song CH, Ahn YK, Han HJ. Role of FAK phosphorylation in hypoxia-induced hMSCS migration: involvement of VEGF as well as MAPKS and eNOS pathways. Am J Physiol Cell Physiol (2010) 298:C847-56. doi:10.1152/ajpcell.00418.2009
81. Jeon ES, Heo SC, Lee IH, Choi YJ, Park JH, Choi KU, et al. Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells. Exp Mol Med (2010) 42:280-93. doi:10.3858/emm.2010.42.4.027
82. Scott A, Weldon S, Buchanan PJ, Schock B, Ernst RK, McAuley DF, et al. Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS ONE (2011) 6:e26525. doi:10.1371/journal.pone.0026525